Actively Recruiting
Led by Zeenat Qureshi Stroke Institute · Updated on 2026-04-24
1000
Participants Needed
13
Research Sites
26 weeks
Total Duration
Z
Zeenat Qureshi Stroke Institute
Lead Sponsor
C
Chiesi USA, Inc.
Collaborating Sponsor
Researchers are studying the use of intravenous clevidipine compared to other intravenous antihypertensive treatments in patients with intracerebral hemorrhage (ICH) who have high blood pressure. The goal is to see how quickly patients achieve a stable target systolic blood pressure (SBP) within 60 minutes of starting treatment. This research is important to better understand blood pressure management in stroke patients with ICH, supported by the Zeenat Qureshi Stroke Institute. The study compares two groups: one receiving IV clevidipine and the other an alternate IV antihypertensive regimen, mainly IV nicardipine, depending on the hospital. Clevidipine is administered starting at 1-2 mg/hour with dosing adjustments every 90 seconds initially, then every 5-10 minutes as blood pressure approaches the goal. Nicardipine starts at 5 mg/hour and is increased every 5-15 minutes until the target blood pressure is reached. Both treatments follow specific dosing protocols and maximum daily limits. Participants are adults aged 18 to under 100 years who have had recent stroke symptoms and elevated blood pressure. They undergo blood pressure monitoring every 15 minutes. The study involves consent and follow-up visits at 90 and 180 days. Researchers assess blood pressure stability and neurological function using clinical signs and CT scans. Safety and treatment adherence are monitored throughout the study period, which runs from enrollment through follow-up assessments.
CONDITIONS
Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 72 hours after treatment initiation
Participants have their blood pressure monitored closely following the start of intravenous antihypertensive treatment with clevidipine or an alternate regimen as part of routine care.
Continuous blood pressure monitoring
Total: 13 locations
1
University of California
Irvine, California, United States, 92696-7600
Actively Recruiting
2
Antelope Valley Medical Center
Lancaster, California, United States, 93534
Actively Recruiting
3
Stanford Medical Center (Stanford Health Care)
Palo Alto, California, United States, 94304
Actively Recruiting
4
Cleveland Clinic Martin North Hospital
Stuart, Florida, United States, 34994
Actively Recruiting
5
University of South Florida
Tampa, Florida, United States, 33606
Actively Recruiting
6
Augusta University-Neuroscience Center
Augusta, Georgia, United States, 30912
Actively Recruiting
7
University of Michigan Health-West
Wyoming, Michigan, United States, 49519
Actively Recruiting
8
University of Missouri
Columbia, Missouri, United States, 65212
Actively Recruiting
9
Albany Medical Center
Albany, New York, United States, 12208
Actively Recruiting
10
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029
Actively Recruiting
11
Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
Actively Recruiting
12
UT Southwestern Medical Center
Dallas, Texas, United States, 75390
Actively Recruiting
13
University of Texas Health Science Center San Antonio
San Antonio, Texas, United States, 78229
Actively Recruiting
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Adnan I Qureshi, William Baskett, Joao A Gomes...
https://pubmed.ncbi.nlm.nih.gov/40993486